Recent investigations have centered on the intersection of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor stimulant therapies and dopaminergic neurotransmission. While GIP stimulators are commonly employed for addressing type 2 diabetes, their unexpected im